Caris Life Sciences, Inc. Common Stock (CAI) — the earnings record

Computed on 2026-09-18 from the vendor's per-print history with the Print Record's method — no desk-written read yet. An investment research diary, not advice.

The record at a glance

3/5EPS beats
5/5revenue beats
2 · 1 · 2up · flat · down (+3d, ±3%)
2026-11-04next print

Reactions across the covered prints span -15.5% to +42.2% — the beat column and the reaction column frequently disagree, which is the whole reason the record scores them separately. The street carries est EPS $0.03 · est revenue ~$0.26B into the next print.

Print by print

PrintDateEPSRevenue
Aug 26 2026-08-05 ✗ miss ✓ beat
May 26 2026-05-07 ✓ beat ✓ beat
Feb 26 2026-02-26 ✓ beat ✓ beat
Nov 25 2025-11-05 ✓ beat ✓ beat
Aug 25 2025-08-12 ✗ miss ✓ beat

Report-day close to the close three sessions later on adjusted closes, ±3% bands — the same method as every hand-written card; the Print Record method explains the bands. No reaction chart, metric line or behavior read exists for CAI yet.

FAQ · from the current data · as of 2026-09-18

Quick answers

How often does Caris Life Sciences, Inc. Common Stock beat earnings estimates?

Across the last 5 covered prints (as of the 2026-09-18 card), Caris Life Sciences, Inc. Common Stock beat EPS estimates 3 of 5 times and revenue estimates 5 of 5 times, with 3 double beats.

How does CAI stock react to earnings?

Measured close-of-print-day to the close three sessions later: 2 of the last 5 prints resolved up (beyond +3%), 1 flat, 2 down — reactions spanning -15.5% to +42.2%. Beat-or-miss and reaction are scored separately because they frequently disagree.

What was CAI's biggest earnings reaction?

+42.2% over the three sessions after the Aug 26 print (2026-08-05).

When does Caris Life Sciences, Inc. Common Stock report earnings next?

2026-11-04 (2026-11-04 · est EPS $0.03 · est revenue ~$0.26B). This record is computed from the vendor's per-print history with the Print Record's method; a desk-written card for CAI does not exist yet. An investment research diary, not advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.